107 related articles for article (PubMed ID: 7552510)
1. Viral phenotype and genotype as markers in clinical trials.
Katzenstein DA
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S25-34. PubMed ID: 7552510
[TBL] [Abstract][Full Text] [Related]
2. Individualization of therapy using viral markers.
Merigan T
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S41-6. PubMed ID: 8595507
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
[TBL] [Abstract][Full Text] [Related]
5. Current HIV clinical trial design issues.
Lange JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S47-51. PubMed ID: 8595508
[TBL] [Abstract][Full Text] [Related]
6. Role of HIV-1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T-cell count.
Kupfer B; Kaiser R; Rockstroh JK; Matz B; Schneweis KE
J Med Virol; 1998 Nov; 56(3):259-63. PubMed ID: 9783695
[TBL] [Abstract][Full Text] [Related]
7. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V
J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973
[TBL] [Abstract][Full Text] [Related]
8. Use and access to viral load measure assays: the need for validation.
Agosto M
Update Natl Minor AIDS Counc; 1995; ():7-8. PubMed ID: 11362791
[TBL] [Abstract][Full Text] [Related]
9. HIV viral load quantification, HIV resistance, and antiretroviral therapy.
Katzenstein DA; Holodniy M
AIDS Clin Rev; 1995-1996; ():277-303. PubMed ID: 7488557
[TBL] [Abstract][Full Text] [Related]
10. Viral load in peripheral blood mononuclear cells as surrogate for clinical progression.
Ferre F; Moss RB; Daigle A; Richieri SP; Jensen F; Carlo DJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S51-6. PubMed ID: 7552513
[TBL] [Abstract][Full Text] [Related]
11. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
[TBL] [Abstract][Full Text] [Related]
12. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.
Goujard C; Bonarek M; Meyer L; Bonnet F; Chaix ML; Deveau C; Sinet M; Galimand J; Delfraissy JF; Venet A; Rouzioux C; Morlat P;
Clin Infect Dis; 2006 Mar; 42(5):709-15. PubMed ID: 16447119
[TBL] [Abstract][Full Text] [Related]
13. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
Atkinson B; Isaacson J; Knowles M; Mazabel E; Patick AK
J Infect Dis; 2000 Aug; 182(2):420-7. PubMed ID: 10915071
[TBL] [Abstract][Full Text] [Related]
14. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
16. The role of phenotyping and replication capacity in anti-HIV therapeutics.
Baliga CS; Sutton RE
Curr Opin Mol Ther; 2004 Jun; 6(3):308-17. PubMed ID: 15264434
[TBL] [Abstract][Full Text] [Related]
17. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.
Rusconi S; De Pasquale MP; Milazzo L; Moscatelli G; Bulgheroni E; Citterio P; d'Arminio-Monforte A; Moroni M; Galli M
Antivir Ther; 1997 Jan; 2(1):39-46. PubMed ID: 11322265
[TBL] [Abstract][Full Text] [Related]
18. Laboratory markers associated with progression of HIV infection.
Kiepiela P; Smith AN; Rosenberg E
Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):243-54. PubMed ID: 15778113
[TBL] [Abstract][Full Text] [Related]
19. HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count.
Jaafar A; Massip P; Sandres-Sauné K; Souyris C; Pasquier C; Aquilina C; Izopet J
J Med Virol; 2004 Sep; 74(1):8-15. PubMed ID: 15258962
[TBL] [Abstract][Full Text] [Related]
20. The V118I mutation as a marker of advanced HIV infection and disease progression.
Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
